Literature DB >> 14653435

Can alzheimer's disease and dementias with Lewy bodies be distinguished clinically?

Myron F Weiner1, Linda S Hynan, Bhavin Parikh, Nasir Zaki, Charles L White, Eileen H Bigio, Anne M Lipton, Kristin Martin-Cook, Doris A Svetlik, C Munro Cullum, Steven Vobach, Roger N Rosenberg.   

Abstract

To determine if Alzheimer's disease (AD), its Lewy body (LB) variant (LBV), and diffuse LB disease (DLBD) are distinguishable at initial clinical evaluation, data from autopsy-confirmed AD, LBV, and DLBD were examined. No significant differences were found in age at onset, age at death, total duration of illness, duration of illness before initial visit, duration of illness from initial visit to death, or severity of illness at initial evaluation. Hallucinations and delusions were significantly more frequent for LBV and DLBD, respectively, than for AD, and falls were more frequent for DLBD than for AD. Extrapyramidal symptoms (EPS) were less frequent in neuroleptic-free AD subjects than in LB subjects; the percentage of AD patients with EPS after neuroleptic exposure was less than that among LB patients. Seizures were significantly more common for DLBD than for AD or LBV. LB dementias differed from AD at initial evaluation, with more frequent hallucinations and delusions, EPSs, and seizures, and longitudinally in neuroleptic sensitivity, but the data did not distinguish LBV from DLBD.

Entities:  

Mesh:

Year:  2003        PMID: 14653435     DOI: 10.1177/0891988703258671

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  13 in total

1.  Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.

Authors:  Elena L Paley; Galina Denisova; Olga Sokolova; Natalia Posternak; Xukui Wang; Anna-Liisa Brownell
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 2.  Distinguishing Alzheimer's disease from other major forms of dementia.

Authors:  Stella Karantzoulis; James E Galvin
Journal:  Expert Rev Neurother       Date:  2011-11       Impact factor: 4.618

3.  Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy.

Authors:  Johanna L Crimins; Anne B Rocher; Jennifer I Luebke
Journal:  Acta Neuropathol       Date:  2012-09-14       Impact factor: 17.088

4.  Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies.

Authors:  Guerry M Peavy; Steven D Edland; Belinda M Toole; Lawrence A Hansen; Douglas R Galasko; Ann M Mayo
Journal:  Parkinsonism Relat Disord       Date:  2016-07-21       Impact factor: 4.891

5.  Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia.

Authors:  Laura S Boylan; Scott Hirsch
Journal:  BMJ Case Rep       Date:  2009-02-02

6.  Association between male gender and cortical Lewy body pathology in large autopsy series.

Authors:  Peter T Nelson; Frederick A Schmitt; Gregory A Jicha; Richard J Kryscio; Erin L Abner; Charles D Smith; Linda J Van Eldik; William R Markesbery
Journal:  J Neurol       Date:  2010-06-20       Impact factor: 4.849

Review 7.  The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment.

Authors:  Rawan Tarawneh; David M Holtzman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

8.  UPDATE ON DEMENTIA WITH LEWY BODIES.

Authors:  Stella Karantzoulis; James E Galvin
Journal:  Curr Transl Geriatr Exp Gerontol Rep       Date:  2013-09-01

9.  Seizures in corticobasal degeneration: a case report.

Authors:  Vanja C Douglas; Stephen J DeArmond; Michael J Aminoff; Bruce L Miller; Gil D Rabinovici
Journal:  Neurocase       Date:  2009-06-18       Impact factor: 0.881

Review 10.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.